BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
December 05, 2024 06:45 ET
|
BioRestorative Therapies, Inc
– Covers cGMP manufacturing processes – – Expected to provide protection until April 29, 2040 – MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”,...
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
November 13, 2024 07:00 ET
|
BioRestorative Therapies, Inc
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in...
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024 16:05 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
November 06, 2024 07:00 ET
|
BioRestorative Therapies, Inc
– New blinded preliminary safety and efficacy data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in podium presentation on November 13, 2024 – – Data will be on a significantly...
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
November 05, 2024 07:10 ET
|
BioRestorative Therapies, Inc
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative...
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
October 31, 2024 07:00 ET
|
BioRestorative Therapies, Inc
– Further expands already formidable intellectual property estate the Company has been building for its novel ThermoStem® technology platform – MELVILLE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) --...
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
October 10, 2024 07:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 10, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 03, 2024 16:15 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
September 19, 2024 06:55 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused...
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024 16:05 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...